GBM AGILE: Information for patients
Below are some frequently asked questions about GBM AGILE. We will update this page on a regular basis as new information comes to hand. If you have been diagnosed with brain cancer and want information about how to get on a clinical trial you should speak to your doctor. More information about clinical trials is available at clinicaltrials.gov
UPDATED DEC 20, 2016
What is Cure Brain Cancer Foundation’s role in GBM AGILE and who is responsible for the trial?
The Foundation has both catalysed and provided seed funding for GBM
AGILE. The GBM AGILE executive committee, based mainly in the USA is developing
the trial protocol and managing the trial.
How can I
get on this trial?
this stage, in Australia, it is envisaged that there will be sites in
Brisbane, Sydney and Melbourne. No further information on specific sites is
available at this stage. Information about the trial, including start dates
will be listed on the clinical trial registries when the trial enrols.
When will it
A number of important regulatory steps must be taken before GBM AGILE opens to patients and once they have been addressed we will provide a further update in early 2017.
Click here for a full update.
How many people will be enrolled on this trial?
current estimate is that, over time, around 300 Australians will be enrolled
within a total of approximately 3000 patients worldwide.
Will I be eligible?
protocol is currently still in development so eligibility criteria are yet to
be finalised. We can confirm that this trial will only be enrolling GBM
What treatments will be trialed?
The agents that will be assessed through the trial have not yet been determined. They may include immunotherapies, targeted agents and chemotherapies that are identified as promising by the ‘Agent Selection’ sub-committee.
Why is this
trial only focused on GBM?
or glioblastoma, a grade IV astrocytoma, is widely recognised to be one of the
most common and the most deadly brain tumour in adults with most people
surviving fewer than 15 months post-diagnosis.
children be eligible to go on the trial?
The protocol is still being developed, but it now looks unlikely that paediatric patients will be able to participate in the early stages of the trial.
Other clinical trials for GBM patients in Australia